UNSPSC 41181946: Gene expression profiling test system for breast cancer prognosis tests

In this classification, a Gene expression profiling test system for breast cancer prognosis tumor associated antigen immunological test system that consists of the reagents used to identify by immunochemical techniques Gene expression profiling test system for breast cancer prognosis based tumors. US FDA regulates Gene expression profiling test system for breast cancer prognosis under 21 CFR 866.6040and under FDA product code NYI.

UNSPSC 41181946 Gene expression profiling test system for breast cancer prognosis tests is a Commodity code. The recent state and local opportunities tagged to this code show minimal alignment with gene expression profiling or oncology diagnostics; instead, they track laboratory services, equipment repair, and testing-system procurement across health departments, utilities, transit authorities, and municipalities. Marion County, Oregon issued an ITB for laboratory testing services and phlebotomy for Adults in Custody (due July 24, 2026), while the Texas Department of State Health Services sought bids for laboratory equipment repair and maintenance at its South Texas Laboratory (due July 6, 2026 under IFB HHS0017421). The City of Tampa issued an RFQ for a replacement Heck DR4900 Spectrophotometer at its McKay Bay Waste to Energy facility (due June 12, 2026), and Lubbock Power & Light requested proposals for annual insulating oil testing and laboratory services for electrical equipment across approximately 20 substations (RFP due July 22, 2026). Additional recent postings include a sole-source notice from the City of Orlando for technical support on a FIAnalyzer-3000 System (May 11, 2026), Broward County Transportation's solicitation for ChargePoint DC Chargers repair and maintenance (May 5, 2026), and the County of Santa Clara's RFI for a Public Health Lab Information Management Solution Replacement (April 22, 2026).

The issuing bodies span state health departments, county transportation and toll authorities, municipal utilities and solid waste programs, and special districts. None of the recent opportunities explicitly solicit gene expression profiling systems, oncology diagnostics, or cancer prognosis testing. The geographic spread includes Oregon, Texas, Florida, and California, with activity concentrated among utility, transportation, and environmental testing operations rather than clinical or research cancer diagnostics. The code exhibits low activity relevance to its nominal commodity scope; state and local procurement offices appear to have misaligned this code with routine laboratory operations, equipment maintenance, and environmental or utility testing services rather than specialized molecular oncology diagnostics.